Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after the rare-disease drug developer reported 2023 fourth-quarter earnings, which caused the market to dump its shares to the tune of 13%.
Here's what Shoenhaus could be thinking will catalyze a reversal for this stock.
In January, Recursion made an interesting decision regarding one of the assets it's developing in its fibrotic disease collaboration with .
Source Fool.com
Bayer AG Aktie
25,81 €
1,69 %
Die Community bevorzugt leicht Bayer AG mit mehr Buy- als Sell-Einschätzungen.
Eine Steigerung von über 20% ist für Bayer AG möglich, angesichts eines Kursziels von 34 € gegenüber 25.81 €.
